Compound, and preparation method therefor and use thereof

By developing fluorinated new indocyanine chlorane and combining the reaction of IR dye compounds, a developer for nuclear magnetic resonance imaging was prepared, which solved the problem of low background interference and signal-to-noise ratio in fluorescence imaging and MRI diagnosis, achieving dual Imaging effects and reduce synthesis costs and background interference.

WO2024240170A1PCT designated stage expired Publication Date: 2024-11-28SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/094647
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The existing fluorescence imaging technology has problems such as large background interference, low signal-to-noise ratio and poor specificity in preoperative diagnosis, and 1H MRI contrast agents have shortcomings such as dual imaging process, high dose and toxicity, and the research on dual imaging molecules is relatively vacant.

Method used

Developed a fluorinated new indocyanine chlorane with a structure including specific CF3 and indole salt groups prepared by reacting with IR dye compounds and used as a developer in nuclear magnetic resonance imaging, achieving low levels with 19F nuclides Dual imaging effect of background interference.

Benefits of technology

The dual imaging capability with low background interference is achieved, which can be used for both fluorescence imaging labeling and preoperative diagnosis of 19F MRI, reducing synthesis costs and avoiding background signal interference during 1H MRI.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094647_28112024_PF_FP_ABST
    Figure CN2024094647_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of chemistry, and in particular relates to a compound, and a preparation method therefor and the use thereof. The compound has a general structural formula as shown in formula I-1 or I-2: wherein R1 and R4 are each independently selected from C(CF3)3, CH(CF3)2 and CH2CF3; R2, R3, R5, and R6 are each independently selected from a benzoindole salt, an indole-like salt, a benzoindole salt, and an indole salt; and n1 and n2 are each independently selected from 1-5. The compound of the present invention can be applied to nuclear magnetic resonance imaging. The compound of the present invention can be used for fluorescence-magnetic resonance dual imaging, wherein fluorescence imaging can be used for intraoperative marking, and magnetic resonance imaging can be used for preoperative diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

A compound and its preparation method and application Technical Field

[0001] The present invention relates to the field of chemical imaging, and in particular to a compound, a preparation method and an application thereof. Background Art

[0002] Fluorescence imaging is currently one of the more mainstream methods in biological imaging. Some dye molecules can bind to cells, enabling cellular imaging. Research on near-infrared dyes as fluorescent markers and sensors has garnered increasing attention over the past decade due to their potential to advance and facilitate the translation of optical imaging into humans. Compared to blue-shifted dyes, near-infrared fluorescent probes offer several advantages: (a) near-infrared light is poorly absorbed by hemoglobin, water, and lipids, resulting in deep tissue penetration; (b) background autofluorescence is negligible; and (c) light scattering in tissue is relatively low, as scattering decreases with increasing wavelength. Near-infrared dyes used for in vivo optical imaging mostly belong to the carbocyanine family. These dyes are the most prominent class of optical imaging agents, possessing tunable optical properties and high extinction coefficients. Furthermore, carbocyanine dyes can be conjugated to antibodies, peptides, or small targeting ligands to impart molecular specificity. Using small amounts of these near-infrared agents, high specificity and good tissue penetration can be achieved. Indocyanine green (ICG) has been approved by the FDA for many clinical imaging applications, and new indocyanine green (IR820), a derivative of ICG, can also be used for near-infrared fluorescence imaging. However, fluorescence imaging can currently only be used during surgery. For preoperative diagnosis, characterization requires additional drug molecules or adjuvants, making the treatment process more complicated.

[0003] Magnetic resonance imaging (MRI), a noninvasive method, is one of the most commonly used medical imaging techniques for disease diagnosis and treatment assessment. It offers adjustable soft-tissue contrast, high spatial and temporal resolution, and the ability to provide high-resolution images without the limitations of ionizing radiation and tissue depth. Because water accounts for 60% of human body weight, imaging its local concentration and relaxation states can provide useful anatomical and physiological information. Therefore, 1H MRI, which uses water protons as a signal source, has been widely used in clinical diagnosis. However, the ubiquity of water in biological systems results in a high background signal, resulting in a low signal-to-noise ratio (SNR), low sensitivity, and poor specificity, making it difficult to distinguish the target region from its surroundings. Consequently, many 1H MRI techniques require contrast agents, such as gadolinium(III), manganese(II) chelates, and iron oxide nanoparticles, to enhance the resolution of the target region. However, 1H MRI contrast agents also have drawbacks, such as double imaging, high dose, and toxicity. Furthermore, contrast agent-assisted 1H MRI is not reliable for quantifying target regions in biological systems. Meanwhile, fluorescence imaging of dye molecules can only be used for intraoperative labeling; preoperative diagnosis requires characterization with other drug molecules or adjuvants. Currently, research on dual-imaging molecules is relatively lacking. Therefore, finding an imaging method with minimal background interference is particularly important.

[0004] Summary of the Invention

[0005] The present invention aims to solve the shortcomings of the prior art and provides a new fluorinated indocyanine green alkane and a preparation method and application thereof.

[0006] The first aspect of the present invention provides a compound having the general structural formula shown in Formula I-1 or I-2:

[0007] Wherein, R1 and R4 are each independently selected from C(CF3)3, CH(CF3)2 and CH2CF3; R2, R3, R5, R6 are each independently selected from benzindole-like salts, indole-like salts, benzindole salts, indole salts; n1 and n2 are each independently selected from 1-5.

[0008] Preferably, R1 and R4 are each independently selected from C(CF3)3;

[0009] R2 is selected from R3 is selected from

[0010] R5 is independently selected from

[0011] R6 is independently selected from

[0012] n1 and n2 are each independently selected from 1, 2, 3, 4, and 5. In the present invention, in the R2, R3, R4, and R5 groups, "*" represents a connection site.

[0013] Preferably, the compound represented by formula I-1 or I-2 is selected from any one or more of the following chemical structures:

[0014] The second aspect of the present invention provides a method for preparing the above-mentioned compound, wherein the compound of formula II-1 is reacted with an IR dye compound to obtain a compound as shown in formula I-1 or I-2. The reaction scheme is as follows:

[0015] Wherein, R1 and R4 are each independently selected from one of C(CF3)3, CH(CF3)2 and CH2CF3; R2, R3, R5, R6 are each independently selected from one of benzoindole-like salt, indole-like salt, benzindole salt and indole salt, R7 is selected from one of C(CF3)3, CH(CF3)2 and CH2CF3, and n1, n2, and n3 are each independently selected from 1-5.

[0016] Preferably, the method specifically includes the following steps:

[0017] A solution containing a compound of formula II-1 is reacted with a solution containing an IR dye compound in the presence of a base to obtain a mixed solution containing the compound as shown in formula I-1 and / or I-2, and then the solvent is removed from the mixed solution, and column chromatography is performed to obtain the compound as shown in formula I-1 and / or I-2.

[0018] Preferably, it includes at least one of the following technical features:

[0019] 1) The solvent used in the solution containing compound II-1 is DMF, the chemical name of DMF is N,N-dimethylformamide;

[0020] 2) The IR dye compound solution is obtained by dissolving the IR dye compound of formula in a first solvent; preferably, the IR dye compound solution is obtained by adding the IR dye compound into a reagent bottle, replacing the protective gas, and then adding the first solvent for dissolution;

[0021] 3) The solvent of the IR dye compound solution is ultra-dry DMF;

[0022] 4) The concentration of the IR dye compound is 0.1 mol / L-1 mol / L;

[0023] 5) the molar ratio of the II-1 compound to the IR dye compound is 2-5:1;

[0024] 6) The base is an organic base; the organic base is added to make The amino groups in the IR dye are released and can attack the chlorine atoms in the IR dye.

[0025] 7) The reaction temperature is 50-70°C;

[0026] 8) The reaction time is 3-12 hours;

[0027] 9) The reaction is carried out in a dark environment; because the IR dye compound is easily deteriorated by light and heat, avoiding light ensures that it does not deteriorate during the reaction;

[0028] 10) removing the solvent by reducing the pressure;

[0029] 11) The solvent for column chromatography separation is a mixed solution of dichloromethane (DCM) and methanol (MeOH).

[0030] Preferably, it includes at least one of the following technical features:

[0031] A1) In feature 1), the molar ratio of the II-1 compound to the DMF is 0.1-1:1;

[0032] A2) In feature 2), the IR dye compound is selected from one or more of IR820 (CAS), IR806 (CAS), IR780 (CAS), IR783 (CAS), and IR1048 (CAS); these dyes are a prominent class of optical imaging agents, possessing tunable optical properties and high extinction coefficients. Furthermore, carbocyanine dyes can be conjugated to antibodies, peptides, or small targeting ligands to impart molecular specificity. Using small amounts of these near-infrared agents can achieve high specificity and good tissue penetration.

[0033] A3) In feature 2), the reagent bottle is a Schlenk bottle;

[0034] A4) In feature 2), the protective gas is selected from one or more of nitrogen, argon and helium;

[0035] A5) In feature 2), the shielding gas is replaced 2-5 times;

[0036] A6) In feature 2), the first solvent is ultra-dry DMF;

[0037] A7) In feature 6), the organic base is selected from one or more of triethylamine and diisopropylamine;

[0038] A8) In feature 5), the molar ratio of the IR dye to the organic base is 1:5-10;

[0039] A9) In feature 11), the volume ratio of DCM and MeOH is gradually increased.

[0040] Preferably, it includes at least one of the following technical features:

[0041] A61) In feature A6), the water molecules in the ultra-dry DMF are 30-50 ppm;

[0042] A91) In feature A9), the volume ratio of DCM to MeOH is gradually increased from 10-15:1 to 5-10:1.

[0043] The third aspect of the present invention provides the use of the above-mentioned compound as a developer in magnetic resonance imaging.

[0044] The 19F nucleus has the following unique properties: (1) 19F is the second most sensitive stable nucleus in MRI, with a natural abundance of 100% and a sensitivity of 83% relative to 1H; (2) Fluorinated organic compounds have a wide chemical shift range of approximately 250 ppm (1H has a chemical shift range of only approximately 10 ppm), and the chemical shift is very sensitive to the local environment, molecular structure, and target interaction, which can achieve higher spatial resolution (spatial resolution from 40 μm to 2 mm); (3) 20% of commercially available drugs contain fluorine, which can provide a variety of signal carriers for 19F MRI; (4) Most biological systems do not contain fluorinated compounds and only exist in the form of solid salts in teeth and bones, so there is no endogenous 19F signal, and the physiological concentration of detectable mobile fluorine is below the detection limit (usually less than 10-3 μmol / g wet tissue weight), and background interference is almost negligible. The 19F signal comes only from the fluorinated contrast agent, and the intensity is directly proportional to the local 19F concentration; (5) 19F MRI can be compared with 1H MRI can be used in combination to obtain medical images with more diagnostic value. Therefore, 19F MRI using 19F nuclide can be applied to nuclear magnetic resonance imaging, providing a new medical diagnostic technology route.

[0045] A fourth aspect of the present invention provides a developer comprising the above compound.

[0046] Indocyanine green (ICG) has been approved by the FDA for many clinical imaging applications, and new indocyanine green (IR820), a derivative of ICG, can also be used for near-infrared fluorescence imaging. However, fluorescence imaging is currently limited to intraoperative use. Preoperative diagnosis requires additional drug molecules or adjuvants for characterization, further complicating the treatment process. By introducing fluorine atoms into the IR dye without changing the original IR820 fluorescence imaging, it can be used in 19F MRI imaging. The fluorinated new indocyanine green of the present invention exhibits dual imaging effects: 19F MRI imaging can be used for preoperative diagnosis, and fluorescence imaging can be used for intraoperative labeling, showing great potential for development in the medical field.

[0047] The present invention has at least one of the following beneficial effects:

[0048] 1) The synthesis route of the fluorinated new indocyanine green in the present invention is simple. The raw materials used, except for the dye, are all commercially available, inexpensive chemicals. The dye molecule is relatively expensive, but it is only required in one final reaction, so the synthesis cost is low. The synthesis cost of the present invention is low.

[0049] 2) The fluorinated new indocyanine green alkane of the present invention can be used for fluorescence and magnetic resonance dual imaging, wherein fluorescence imaging can be used for intraoperative labeling, and magnetic resonance imaging can be used for preoperative diagnosis.

[0050] 3) Because fluorine-containing compounds are absent from the human body and exist only as solid salts in teeth and bones, there is no endogenous 19F signal, resulting in minimal background interference. Utilizing the fluorine atoms in fluorinated neoindocyanine green for 19F MRI avoids the high background interference seen with 1H MRI and eliminates the need for additional additives. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] FIG1 is a hydrogen nuclear magnetic resonance spectrum of compound 1 in an embodiment of the present invention.

[0052] FIG2 is a hydrogen nuclear magnetic resonance spectrum of compound 2 in an embodiment of the present invention.

[0053] FIG3 is a hydrogen nuclear magnetic resonance spectrum of compound 3 in an example of the present invention.

[0054] FIG4 is a hydrogen nuclear magnetic resonance spectrum of compound 4 in Example 1 of the present invention.

[0055] FIG5 is a nuclear magnetic resonance fluorine spectrum of compound 4 in Example 1 of the present invention.

[0056] FIG6 is a graph showing the absorption and fluorescence spectra of the fluorinated new indocyanine green and the new indocyanine green in Example 10 of the present invention.

[0057] FIG. 7 is a diagram showing a is compound 4 in Example 11 of the present invention. 19F MRI imaging, b is compound 4 1 H MRI imaging. DETAILED DESCRIPTION

[0058] The following describes the embodiments of the present invention through specific examples. Those skilled in the art will readily understand the other advantages and benefits of the present invention from the disclosure herein. The present invention may also be implemented or applied through various other specific embodiments, and the details in this specification may be modified or altered based on different viewpoints and applications without departing from the spirit of the present invention.

[0059] It should be noted that the process equipment or devices not specifically specified in the following embodiments are all conventional equipment or devices in the art.

[0060] 1) Synthesis

[0061] 4.62mL of redistilled triethylamine, 1.7932g of di-tert-butyl dicarbonate (Boc2O), and 10mL of redistilled tetrahydrofuran (THF) were added to a round-bottom flask and placed in an ice-water bath. 495.1mg of 3-hydroxypropylamine was slowly added to the round-bottom flask with a syringe. The system was kept at 0°C and the reaction solution was stirred for 20 hours. During the reaction, the reaction solution temperature was allowed to rise to room temperature naturally. After the reaction was completed, the solvent was removed by rotary evaporation and the residue was dissolved in ethyl acetate. The mixture was washed with deionized water, and the aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, washed with saturated NaHCO3 aqueous solution and saturated brine, then dried over anhydrous Na2SO4, filtered to remove the desiccant, and rotary evaporation to remove the solvent to obtain compound 1. The yield was 70%, and no additional purification was required. The H NMR spectrum of compound 1 is shown in FIG1 . The H NMR spectrum of compound 1 is shown below: 1 H NMR (400MHz, CDCl3, ppm): δ4.77 (br, 1H), 3.59 (t, J = 6.0 Hz, 2H), 3.21 (t, J = 6.0 Hz, 2H), 2.73 (br, 1H), 1.60 (m, 2H), 1.38 (s, 9H).

[0062] 2) Synthesis

[0063] 625 mg of triphenylphosphine (PPh3) was added to a pre-dried Schlenk bottle, and N2 was replaced three times. 276.7 mg of compound 1 obtained in 1) was taken out. Dissolve in a small amount of ultra-dry THF, add to a Schlenk bottle containing triphenylphosphine (PPh3) with a syringe, and add 6mL ultra-dry THF again, and place in an ice-water bath. Slowly add 423mg of diethyl azodicarboxylate (DEAD) with a syringe, move to room temperature after addition, and stir for 20 minutes. Then quickly add 600mg of perfluorotert-butanol through a syringe, and react at 55°C for 22 hours. After the reaction is completed, the solvent is removed by rotary evaporation, and column chromatography separation (90:10 = PE: EtOAc to 80:20 = PE: EtOAc, gradient elution) to obtain compound 2 The yield is 40%. The H NMR spectrum of compound 2 is shown in FIG2 . The H NMR spectrum of compound 2 is shown below: 1 H NMR (400MHz, CDCl3, ppm): δ4.67 (br, 1H), 4.08 (t, J = 6.0Hz, 2H), 3.23 (d, J = 4.0Hz, 2H), 1.88 (m, 2H), 1.43 (s, 9H).

[0064] 3) Synthesis

[0065] Take 326 mg of compound 2 obtained in 2) Add to a round-bottom flask, add 2.5 mL of ether, then add 0.16 mL of concentrated hydrochloric acid dropwise and stir for 20 h. After the reaction is complete, remove the solvent by rotary evaporation, add a small amount of methanol (about 0.5 mL), and then add about 5 mL of ether to cause phase separation. Transfer the lower layer to a clean round-bottom flask and remove the methanol by rotary evaporation to obtain compound 3 The yield is 45%. The H NMR spectrum of compound 3 is shown in FIG3 . The H NMR spectrum of compound 3 is shown below: 1 H NMR (400MHz, DMSO-d6, ppm): δ8.08 (s, 3H), 4.19 (t, J = 6.0Hz, 2H), 2.86 (s, 2H), 1.98 (m, 2H).

[0066] Example 1

[0067] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Triethylamine was added and the mixture was allowed to react at 60°C in the dark for 4 hours. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield is 57%. The H NMR spectrum of compound 4 is shown in Figures 4 and 5. The H NMR spectrum of compound 4 is shown below: 1 H NMR (400MHz, DMSO-d6, ppm): δ8.13(d,J=8.8Hz,2H),7.98(d,J=3.2Hz,2H),7.96(d,J=4.0Hz,2H),7.75(d,J=13.6Hz 2H),7.69(d,J=8.4Hz,2H),7.56(d,J=7.6Hz,2H),7.39(t,J=7.6Hz,2H),5.87(d,J=12.4Hz,2H),4.18(t,J=7.2Hz,2H),4.10(s,4H), 3.89–3.83(m,2H),3.60(t,J=6.4Hz,4H),2.56–2.54(m,5H),2.24–2.13(m,2H),2.01–1.88(m,4H),1.88(s,12H),1.39–1.31(m,4H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-70.0 (s).

[0068] Example 2

[0069] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Triethylamine was then added and the mixture was allowed to react at 50°C in the dark for 4 h. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 50%.

[0070] Example 3

[0071] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Triethylamine was added and the mixture was allowed to react at 70°C in the dark for 4 h. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 40%.

[0072] Example 4

[0073] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Diisopropylamine was added and the mixture was allowed to react at 60°C in the dark for 4 hours. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 43%.

[0074] Example 5

[0075] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Diisopropylethylamine was then added and the mixture was allowed to react at 60°C in the dark for 4 h. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 40%.

[0076] Example 6

[0077] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Dissolve the compound II-1 in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. 2,6-di-tert-butylpyridine was added and the mixture was allowed to react at 60°C in the dark for 4 hours. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution separation. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 35%.

[0078] Example 7

[0079] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Triethylamine was then added and the mixture was allowed to react at 60°C in the dark for 3 h. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 50%.

[0080] Example 8

[0081] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Triethylamine was added and the mixture was allowed to react at 60°C in the dark for 5 h. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 52%.

[0082] Example 9

[0083] 4.9 mg IR820 was added to a Schlenk bottle, the protective gas was replaced with nitrogen three times, and 1 ml of ultra-dry DMF (water molecules within 50 ppm) was added to dissolve the obtained compound II-2 solution; the obtained compound 3 Compound II-1 was pre-dissolved in 0.5 ml of DMF to obtain a solution, which was then added to the solution of compound II-2. Triethylamine was added and the mixture was allowed to react at 60°C in the dark for 7 hours. After the reaction, the solvent was removed under reduced pressure and column chromatography was performed using a glass column with a height of 300 mm and a radius of 15 mm for gradient elution. During the gradient elution, the volume ratio of DCM:MeOH was gradually reduced from 10:1 to 5:1 to obtain compound 4. The yield was 54%.

[0084] Example 10

[0085] Determination of the UV absorption spectrum and fluorescence spectrum of the dye: Compound 4 in Example 1 was accurately weighed and purified using an analytical balance, and dimethyl sulfoxide (DMSO) was added to Compound 4 to prepare a 1 mmol / L mother solution, which was then stored in a refrigerator at -2 to 8°C for later use.

[0086] When testing the UV-visible absorption spectrum and fluorescence spectrum, 30 μL of the stock solution was taken with a pipette and dissolved in 2970 μL of a centrifuge tube containing DMSO. The mixture was mixed evenly to obtain a concentration of 10 μmol / L of compound 4. The solution was then transferred to a quartz cuvette with a dropper for UV-visible absorption and fluorescence spectrum measurements.

[0087] As shown in Figure 6, the absorption spectrum test results in DMSO show that the maximum absorption wavelength of compound 4 is 676 nm, reaching the near-infrared region (650-900 nm). Compared with the prodrug molecule IR820 of compound 4 (maximum absorption wavelength is 835 nm), the maximum absorption wavelength has a blue shift of 159 nm.

[0088] The test results of the emission spectrum in DMSO show that the maximum emission wavelength of compound 4 is 798 nm, reaching the near-infrared region. Compared with the prodrug molecule IR820 of compound 4 (maximum emission wavelength is 840 nm), the maximum emission wavelength has a blue shift of 42 nm.

[0089] Comparison of the maximum absorption and emission wavelengths of compound 4 with those of the prodrug molecule IR820 reveals that compound 4 exhibits a Stokes shift of 122 nm, while IR820 exhibits a Stokes shift of only 5 nm. This large Stokes shift can significantly reduce the signal-to-noise ratio and fluorescence self-quenching in fluorescence imaging, making it well-suited for in vivo use. Therefore, the fluorinated new indocyanine green of the present invention is well-suited for fluorescence imaging and plays an important role in intraoperative imaging and labeling.

[0090] Example 11

[0091] To test the dye's 19F MRI detection limit, 100 μL of each DMSO solution of 9F-IR820, compound 4 from Example 1, at 20 mM, 10 mM, 5 mM, 2.5 mM, and 0 mM concentrations was added to a 100 μL EP tube, avoiding air bubbles. Each of these five samples was attached to a 1H / 19F surface coil. For topography and 1H imaging, the 1H coil mode was selected, while for 19F imaging, the 19F coil mode was selected. RARE sequences were then performed. Figure 7a shows that the detection limit of 9F-IR820 was 5 mM, and that the sample exhibited 19F MRI efficacy.

[0092] In summary, since the human body lacks fluorinated compounds and exists only as solid salts in teeth and bones, there is no endogenous 19F signal, resulting in minimal background interference. Utilizing the fluorine atoms in fluorinated neoindocyanine green for 19F MRI avoids the high background interference seen with 1H MRI. Furthermore, fluorinated neoindocyanine green offers both fluorescence imaging and 19F magnetic resonance imaging, making it a dual-imaging molecule.

[0093] The above embodiments are merely illustrative of the principles and effects of the present invention and are not intended to limit the present invention. Anyone skilled in the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by one of ordinary skill in the art without departing from the spirit and technical principles disclosed herein are intended to be covered by the claims of the present invention.

Claims

1. A compound, characterized in that It has the general structural formula shown in Formula I-1 or I-2: Wherein, R1 and R4 are each independently selected from C(CF3)3, CH(CF3)2 and CH2CF3; R2, R3, R5, R6 are each independently selected from benzoindole-like salts, indole-like salts, benzindole salts, indole salts; n1 and n2 are each independently selected from 1-5.

2. The compound according to claim 1, characterized in that R1 and R4 are each independently selected from C(CF3)3; R2 is selected from R3 is selected from R5 is independently selected from R6 is independently selected from n1 and n2 are each independently selected from 1, 2, 3, 4, and 5.

3. The compound according to claim 1 or 2, characterized in that The compound represented by formula I-1 or I-2 is selected from any one or more of the following chemical structures:

4. The method for preparing the compound according to any one of claims 1 to 3, characterized in that: The compound of formula II-1 is reacted with an IR dye compound to obtain a compound as shown in formula I-1 or I-2, and the reaction scheme is as follows: Wherein, R1 and R4 are each independently selected from one of C(CF3)3, CH(CF3)2 and CH2CF3; R2, R3, R5, R6 are each independently selected from one of benzoindole-like salts, indole-like salts, benzindole salts and indole salts, R7 is selected from one of C(CF3)3, CH(CF3)2 and CH2CF3, and n1, n2, and n3 are each independently selected from 1-5.

5. The method for preparing the compound according to claim 4, characterized in that: The specific steps include: A solution containing the compound of formula II-1 is reacted with a solution containing an IR dye compound in the presence of a base to obtain a mixed solution containing the compound as shown in formula I-1 and / or I-2, and then the solvent is removed from the mixed solution and column chromatography is performed to obtain the compound as shown in formula I-1 and / or I-2.

6. The method for preparing the compound according to claim 5, characterized in that: Include at least one of the following technical features: 1) The solvent used in the solution containing compound II-1 is DMF; 2) The IR dye compound solution is obtained by dissolving the IR dye compound of formula in a first solvent; preferably, the IR dye compound solution is obtained by adding the IR dye compound into a reagent bottle, replacing the protective gas, and then adding the first solvent for dissolution; 3) The solvent of the IR dye compound solution is super dry DMF; 4) The concentration of the IR dye compound is 0.1 mol / L-1 mol / L; 5) the molar ratio of the II-1 compound to the IR dye is 2-5:1; 6) The base is an organic base; 7) The reaction temperature is 50-70°C; 8) The reaction time is 3-12h; 9) The reaction is carried out in a light-proof environment; 10) removing the solvent is removing the solvent under reduced pressure; 11) The solvent for column chromatography separation is a mixed solution of dichloromethane (DCM) and methanol (MeOH).

7. The method for preparing the compound according to claim 6, characterized in that: Include at least one of the following technical features: A1) In feature 1), the molar ratio of the II-1 compound to the DMF is 0.1-1:1; A2) In feature 2), the IR dye is selected from one of IR820, IR806, IR780, IR783 and IR1048 or There are many kinds of A3) In feature 2), the reagent bottle is a schlenk bottle; A4) In feature 2), the protective gas is selected from one or more of nitrogen, argon and helium; A5) In feature 2), the number of times the protective gas is replaced is 2-5 times; A6) In feature 2), the first solvent is ultra-dry DMF; A7) In feature 6), the organic base is selected from one or more of triethylamine and diisopropylamine; A8) In feature 5), the molar ratio of the IR dye: the organic base is 1:5-10; A9) In feature 11), the volume ratio of DCM and MeOH is gradually increased.

8. The method for preparing the compound according to claim 7, characterized in that: Include at least one of the following technical features: A61) In feature A6), the water molecules in the ultra-dry DMF are 30-50 ppm; A91) In feature A9), the volume ratio of DCM to MeOH is gradually increased from 10-15:1 to 5-10:

1.

9. Use of the compound according to any one of claims 1 to 3 as a developer in magnetic resonance imaging.

10. A developer, characterized in that: The invention comprises the compound according to any one of claims 1 to 3.

Citation Information

Patent Citations

  • Cyanine compound, optical filter, apparatus using optical filter and resin composite

    CN106397300A

  • A lithographic printing plate precursor

    CN112088093A

  • Image-formation material and infrared absorber

    US20040175649A1

  • Laked tris- or tetracationic polymethine dyes

    US5445672A

  • Fluorescence-magnetic resonance bimodal contrast agent, preparation method therefor and use thereof

    WO2022242437A1